Last update: July 20, 2017

Piperacillin + Tazobactam

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Piperacillin (see specific info) is a ureidopenicillin similar to ticarcillin (see specific info).
Tazobactam is added as a beta-lactamase inhibitor with few clinical and pharmacokinetic effects similar to that of piperacillin.

It is excreted into breastmilk in a clinically insignificant amount (Baier 1982, Chaplin 1982, Wyeth 2007).

Because it lacks of oral bioavailability, seems difficult any pass to the infant’s plasma through the breast milk ingested, except on premature infants and immediate neonatal period, in which there may be an increased intestinal permeability.

Authorized use in infants and small infants (Chen 2009).

Be aware of the likelihood of false negative cultures of febrile infants whose mothers are on antibiotics, as well as the possibility of gastroenteritis due to imbalanced intestinal flora.


See below the information of this related product:

Alternatives

We do not have alternatives for Piperacillin + Tazobactam since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Piperacillin + Tazobactam belongs to this group or family:

Tradenames

Main tradenames from several countries containing Piperacillin + Tazobactam in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 536 / 322 daltons
Protein Binding 30 %
VD 10 - 16 l/Kg
Tmax 0,5 - 0,9 hours
T1/2 0,7 - 1,2 hours
Theoretical Dose 0,29 mg/Kg/d
Relative Dose 0,1 - 0,2 %
Relat.Ped.Dose 0,13 - 0,2 %

References

  1. AEMPS. Piperacilina-Tazobactam. Ficha técnica 2015 Full text (in our servers)
  2. Chen HN, Lee ML, Yu WK, Lin YW, Tsao LY. Late-onset Enterobacter cloacae sepsis in very-low-birth-weight neonates: experience in a medical center. Pediatr Neonatol. 2009 Abstract
  3. Wyeth. Piperacillin & Tazobactam Product Information. 2007 Full text (in our servers)
  4. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  5. Chaplin S, Sanders GL, Smith JM. Drug excretion in human breast milk. Adv Drug React Acute Poisoning Rev 1982; 1:255-87. 1982
  6. Baier R, Wolnik L, Puppel H et al. Piperacillin concentrations in milk and serum from lactating women. Proc ICAAC. 1982;203. Abstract 779 (in https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm) 1982
  7. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1978 Abstract

Total visits

11,792

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM